Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Frankel

Showing results (201-210 of 259) with videos related to

Pageof 26
Sort By:
Organic & Biomolecular Chemistry|November 19, 2010
Computational and experimental investigations of mono-septanoside binding by Concanavalin A: correlation of ligand stereochemistry to enthalpies of bindingMichael R Duff, W Sean Fyvie, Shankar D Markad, et al.
The Journal of Clinical Investigation|September 1, 1985
Characterization of immunotoxins active against ovarian cancer cell linesR Pirker, D J FitzGerald, T C Hamilton, et al.
Clinical Breast Cancer|April 10, 2021
A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane TherapyBarbara Haley, Kiran Batra, Sunati Sahoo, et al.
Frontiers in Bioscience (Landmark Edition)|March 11, 2009
Pathophysiology of anthraxArthur E Frankel, Shu-Ru Kuo, David Dostal, et al.
Cancer Research|July 15, 1989
Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugateL M Weiner, J O'Dwyer, J Kitson, et al.
Biochemistry|August 27, 1996
Structure and activity of an active site substitution of ricin A chainP J Day, S R Ernst, A E Frankel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude miceRalph J Abi-Habib, Ravibhushan Singh, Stephen H Leppla, et al.
Current Drug Targets|February 10, 2009
Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphomaA E Frankel, S L Zuckero, A A Mankin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptorPhilippe Depeille, John J Young, Elissa A Boguslawski, et al.
Journal of Immunological Methods|October 16, 1996
Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignanciesD A Vallera, L J Burns, A E Frankel, et al.
Pageof 26

Showing results (201-210 of 259) with videos related to

Sort By:
Pageof 26
Organic & Biomolecular Chemistry|November 19, 2010
Computational and experimental investigations of mono-septanoside binding by Concanavalin A: correlation of ligand stereochemistry to enthalpies of bindingMichael R Duff, W Sean Fyvie, Shankar D Markad, et al.
The Journal of Clinical Investigation|September 1, 1985
Characterization of immunotoxins active against ovarian cancer cell linesR Pirker, D J FitzGerald, T C Hamilton, et al.
Clinical Breast Cancer|April 10, 2021
A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane TherapyBarbara Haley, Kiran Batra, Sunati Sahoo, et al.
Frontiers in Bioscience (Landmark Edition)|March 11, 2009
Pathophysiology of anthraxArthur E Frankel, Shu-Ru Kuo, David Dostal, et al.
Cancer Research|July 15, 1989
Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugateL M Weiner, J O'Dwyer, J Kitson, et al.
Biochemistry|August 27, 1996
Structure and activity of an active site substitution of ricin A chainP J Day, S R Ernst, A E Frankel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude miceRalph J Abi-Habib, Ravibhushan Singh, Stephen H Leppla, et al.
Current Drug Targets|February 10, 2009
Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphomaA E Frankel, S L Zuckero, A A Mankin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptorPhilippe Depeille, John J Young, Elissa A Boguslawski, et al.
Journal of Immunological Methods|October 16, 1996
Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignanciesD A Vallera, L J Burns, A E Frankel, et al.
Pageof 26